Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IST:ANGEN's EV-to-FCF is ranked worse than 100% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.015
vs IST:ANGEN: -15.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's PE Ratio (TTM) for today is calculated as:
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's share price for today is ₺10.19.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺-1.399.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve EV-to-FCF Related Terms
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve EV-to-FCF Chart
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve EV-to-FCF vs Medical Devices & Instruments Industry
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's current Enterprise Value is ₺2,603.7 Mil.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺-170.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) has a EV-to-FCF of -15.30 as of Jul. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve and its competitors. According to the industry distribution chart, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve ranks #999999 out of 414 companies in the Medical Devices & Instruments industry.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's EV-to-FCF too high?
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's current EV-to-FCF is -15.30. Based on the distribution chart, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve ranks #999999 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve ranks #999999 out of 414 companies for EV-to-FCF. This places Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve in the lower half of its industry. The industry median EV-to-FCF is 23.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.02, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's current EV-to-FCF is -15.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve stock overvalued right now?
Based on GuruFocus' analysis, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₺18.66, compared to a current price of ₺10.19 — trading 45.4% below its estimated fair value. The current EV-to-FCF is -15.30. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN), the current EV-to-FCF is -15.30 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve stock appears to be undervalued.
The current stock price of ₺10.19 is trading 45.4% below its estimated GF Value™ of ₺18.66.
GuruFocus considers Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve to be Possible Value Trap.
Key valuation signals for IST:ANGEN:
EV-to-FCF: -15.30
GF Value™: ₺18.66 vs. price of ₺10.19 (45.4% below fair value)
No single metric tells the full story. See the IST:ANGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Business Description
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS is an international biotechnology company. It is engaged in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments. It also manufactures NA Extraction kits, Microbiology kits, Genetic Disorders kits, Panel kits, Sequencing kits, Food Testing kits.
58GF Score
Get the complete analysis for IST:ANGEN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ANGEN has been successfully added to your 
